ebola
viru
negativesens
singl
strand
rna
viru
famili
filovirida
sinc
discoveri
ebola
virus
caus
numer
outbreak
sever
hemorrhag
fever
africa
emerg
ebola
viru
diseas
evd
guinea
spread
urban
center
neighbor
west
african
countri
recent
caus
intern
alarm
filoviru
infect
character
acut
onset
ill
incub
period
day
initi
symptom
fever
chill
myalgia
malais
diseas
sign
symptom
frequent
becom
sever
mani
patient
featur
system
inflammatori
respons
syndrom
fever
tachycardia
hyperventil
less
frequent
leukopenia
organ
dysfunct
sever
sepsi
shock
also
common
howev
capillari
leak
syndrom
subsequ
secondari
lung
injuri
hypoxia
much
less
appar
typic
bacteri
sepsi
includ
termin
phase
result
death
prolong
convalesc
period
depend
variou
host
viral
factor
death
shock
multiorgan
failur
typic
occur
within
day
symptom
onset
casefat
rate
evd
current
specif
therapi
avail
demonstr
efficaci
treatment
ebola
hemorrhag
fever
search
filoviru
therapeut
histor
challeng
convent
antivir
strategi
ribavirin
recombin
treatment
convalesc
antisera
proven
ineffect
anim
trial
howev
exampl
differ
approach
demonstr
surviv
benefit
nucleosid
analogu
inhibitor
cellencod
enzym
sadenosylhomocystein
hydrolas
sah
shown
inhibit
zair
ebolaviru
replic
adult
balbc
mice
infect
mouseadapt
ebola
viru
inhibit
sah
indirectli
inhibit
transmethyl
reaction
requir
viral
replic
smith
et
al
found
rhesu
macaqu
infect
lethal
dose
ebola
viru
treatment
interferon
beta
earli
exposur
led
signific
increas
surviv
time
though
reduc
mortal
significantli
passiv
immun
attempt
use
equinederiv
hyperimmun
globulin
humanderiv
convalesc
immun
globulin
prepar
ebola
virusinfect
cynomolgu
macaqu
use
human
recombin
interferon
conjunct
hyperimmun
equin
immunoglobulin
g
igg
delay
prevent
death
outbreak
kikwit
democrat
republ
congo
human
convalesc
plasma
use
treat
eight
patient
proven
ebola
diseas
one
patient
die
subsequ
studi
could
demonstr
surviv
benefit
confer
convalesc
plasma
product
surviv
patient
suggest
passiv
immun
may
benefit
patient
dna
vaccin
express
either
envelop
gp
nucleocapsid
protein
np
gene
ebola
viru
demonstr
induc
protect
adult
mice
expos
viru
vaccin
administ
coat
gold
bead
dna
express
gene
either
gp
np
deliv
skin
particl
bombard
use
powderjectxr
gene
gun
vaccin
induc
measur
antibodi
respons
detect
enzymelink
immunosorb
assay
induc
cytotox
tcell
immun
experiment
therapi
use
avail
drug
though
approv
us
food
drug
administr
treatment
ebola
viru
infect
may
consid
agent
may
reduc
mortal
without
directli
effect
viral
replic
includ
activ
protein
c
recombin
nematod
anticoagul
protein
nap
inhibit
activ
factor
viitissu
factor
complex
nap
result
attenu
coagulopathi
associ
decreas
fibrinolysi
fibrin
deposit
result
decreas
sever
system
inflammatori
respons
syndrom
strategi
describ
provid
protect
administ
either
shortli
lethal
challeng
absenc
licens
prophylaxi
treatment
support
care
individu
patient
fraught
difficulti
evok
widespread
suspicion
fear
affect
commun
current
procedur
deal
suspect
confirm
case
includ
disrupt
viru
transmiss
form
quarantin
barrier
protect
palli
care
yet
sign
outbreak
abat
pathogenesi
evd
human
remain
poorli
understood
usual
studi
model
infect
nonhuman
primat
valuabl
insight
gain
rodent
model
constrain
differ
clinic
featur
common
pathogezn
featur
viral
haemorrhag
fever
virus
abil
disabl
host
immun
respons
attack
manipul
cell
initi
antivir
respons
end
organ
dysfunct
evd
result
combin
direct
injuri
virusinfect
tissu
indirect
effect
immun
respons
within
outbreak
viral
strain
variat
limit
host
respons
main
determin
outcom
recoveri
ebola
infect
associ
earli
wellregul
inflammatori
respons
includ
earli
antibodi
product
reduc
cell
apoptosi
rapid
clearanc
viraemia
compar
fatal
case
strategi
provid
cheap
easili
administ
potent
viru
inhibit
patient
display
evd
remain
elus
may
get
clue
previou
observ
larg
outbreak
human
enteroviru
associ
handfootandmouth
diseas
hfmd
china
march
may
result
case
includ
death
clinic
characterist
outbreak
china
mainli
associ
central
nervou
system
cn
involv
systemat
compar
chang
peripher
lymphocyt
subset
patient
without
cn
complic
result
demonstr
signific
increas
absolut
count
percentag
b
lymphocyt
children
symptom
enceph
acut
stage
follow
rapid
recoveri
paramet
normal
level
week
later
convalesc
stage
igg
level
significantli
higher
cn
group
compar
mild
case
appear
immunophenotyp
chang
associ
sever
clinic
manifest
hfmd
hypothes
patient
sever
infect
rapid
recoveri
cn
complic
relat
restor
igg
level
b
cell
acut
phase
intraven
immunoglobulin
ivig
treatment
previou
studi
ivig
therapi
shown
suscept
chronic
enteroviru
infect
administr
ivig
could
amelior
diseas
immunoglobulin
larg
yshape
protein
produc
bcell
plasma
cell
ivig
use
replac
dose
mg
kg
weekli
treat
patient
primari
antibodi
defici
highdos
ivig
use
immunomodulatori
agent
wide
rang
autoimmun
inflammatori
disord
well
bacteri
viral
infect
respond
convent
therapi
ivig
prepar
pool
plasma
high
number
donor
frequent
use
label
mani
autoimmun
condit
sever
mechan
action
ivig
propos
includ
matur
antigenpres
cell
induct
regulatori
tcell
subset
gener
antiinflamatori
capac
recent
data
suggest
presenc
natur
antibodi
may
key
biolog
relev
ivig
activ
enhanc
mainten
cellular
tissu
homeostasi
via
stimul
cell
surfac
receptor
gorochov
et
al
identifi
larg
plasmacel
mobil
exclus
ivigtr
autoimmun
patient
day
initi
treatment
major
ivigmobil
plasma
cell
immatur
plasma
cell
express
intracellular
immunoglobulin
g
neither
ivignor
human
iggspecif
strong
neg
correl
note
absolut
number
ivigmobil
plasma
cell
time
improv
neurolog
function
guillainbarr
syndrom
gb
made
conclus
ivig
promot
immatur
plasma
cell
mobil
patient
gb
promin
day
plasmacel
mobil
favor
prognost
marker
patient
gb
receiv
ivig
treatment
seek
optim
antivir
strategi
could
easili
obtain
could
afford
underdevelop
countri
use
ivig
replac
therapi
patient
primari
ab
defici
still
main
indic
field
infecti
diseas
treatment
prevent
like
modul
inflammatori
respons
tissu
affect
viral
pathogen
also
play
import
role
modul
diseas
hyperimmun
immunoglobulin
use
success
treat
wnvinduc
enceph
ivig
reduc
mortal
combin
antivir
drug
adult
hsct
recipi
respiratori
syncyti
viru
infect
ivig
therapi
initi
onset
sever
respiratori
failur
antipathegenspecif
immunemodulatori
effect
may
supplement
ivig
may
help
reequilibr
rel
proport
specif
natur
occur
ab
noab
could
base
benefici
effect
observ
patient
hiv
influenza
infect
therefor
also
make
hypothesi
evd
could
also
benefit
intervent
ivig
earli
stage
diseas
experiment
result
could
learn
evd
treatment
past
sever
decad
wait
vanish
spontan
ivig
current
use
wide
rang
clinic
condit
may
probabl
also
work
viral
infect
especi
viru
respond
convent
antivir
strategi
ebola
viru
clinic
relev
concern
mechan
action
highlight
although
knowledg
molecular
mechan
specif
condit
rel
limit
